INHIBITION OF PROSTATE-CANCER GROWTH BY ESTRAMUSTINE AND COLCHICINE

被引：27

作者：

FAKIH, M

YAGODA, A

REPLOGLE, T

LEHR, JE

PIENTA, KJ

机构：

[1] WAYNE STATE UNIV,SCH MED,MEYER L PRENTIS COMPREHENS CANC CTR,DIV HEMATOL ONCOL,DETROIT,MI

[2] MICHIGAN CANC FDN,DETROIT,MI 48201

[3] COLUMBIA PRESBYTERIAN MED CTR,DIV MED ONCOL,NEW YORK,NY 10032

来源：

PROSTATE | 1995年 / 26卷 / 06期

关键词：

PROSTATE CANCER; ESTRAMUSTINE; COLCHICINE; PC-3; DUNNING MAT-LYLU;

D O I：

10.1002/pros.2990260606

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hormone-refractory prostate cancer continues to be associated with a very poor prognosis. Agents that inhibit microtubule function have been found to be cytotoxic to prostate cancer cells in preclinical and clinical settings. It was the aim of this study to assess the activity of estramustine and colchicine, two microtubule inhibitors, in hormone-refractory prostate cancer. In clinically achievable concentrations, the combination of estramustine and colchicine was cytotoxic to both the Dunning rat prostate adenocarcinoma cell line MAT-LyLu (MLL) and human prostate cancer cells (PC-3). Microtubule function was assessed in vitro to evaluate possible mechanisms of action. In motility and cell cycle analysis assays, estramustine and colchicine inhibited cellular motility but not cell cycle transit. In vivo, these two agents both inhibited the growth of implanted Dunning rat prostate adenocarcinoma MLL cells but did not appear to have additive effects. The use of oral colchicine in the treatment of hormone-refractory prostate cancer requires further investigation. (C) 1995 Wiley-Liss, Inc.

引用

页码：310 / 315

页数：6

共 16 条

[1]

Yagoda A, Petrylak D, Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancer, Cancer, 71, pp. 1098-1109, (1993)

[2]

Dexeus F, Logothetis CJ, Samuels ML, Continuous infusion of vinblastine for advanced hormone‐refractory prostate cancer, Cancer Treat Rep, 69, pp. 885-886, (1985)

[3]

Pienta KJ, Coffey DS, Cell motility as a target for cancer chemotherapy, Cancer Surv, 11, pp. 255-265, (1991)

[4]

Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T, Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer, J Urol, 147, pp. 931-934, (1992)

[5]

Hudes GR, Greenberg R, Krigel RL, Fox S, Scher R, Litwin S, Watts P, Speicher LS, Tew K, Comis R, Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone refractory prostate cancer, J Clin Oncol, 10, pp. 1754-1761, (1992)

[6]

Amato RJ, Logothetis CJ, Dexeus FH, Sella A, Kilbourn RG, Fitz K, Preliminary results of phase II trial of estramustine (EMCYT) and vinblastine (VLB) for patients (pts) with progressive hormone refractory prostate carcinoma (HRPC), Proc Am Assoc Cancer Res, 32, (1991)

[7]

Tew KD, Stearns ME, Hormone‐independent, non‐alkylating mechanism of cytotoxicity for estramustine, Urol Res, 15, pp. 155-160, (1987)

[8]

Speicher LA, Barone L, Tew KD, Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines, Cancer Res, 52, pp. 4433-4440, (1992)

[9]

Pienta KJ, Isaacs WB, Vindivich D, Coffey DS, The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells, J Urol, 145, pp. 199-202, (1991)

[10]

Pienta KJ, Lehr JE, Inhibition of prostate cancer growth by estramustine and etoposide: Evidence for interaction at the nuclear matrix, J Urol, 149, pp. 1622-1625, (1993)

← 1 2 →